Treatment-naїve mantle cell lymphoma (MCL) research hub

A Randomized, Double-Blind, Multicenter, Placebo-Controlled Phase 3 Study of Orelabrutinib in Combination with Rituximab and Bendamustine (BR) vs. BR in Subjects with Treatment-Naїve Mantle Cell Lymphoma

This study is looking at a new treatment for a type of blood cancer called Mantle Cell Lymphoma. It compares a new drug called orelabrutinib along with standard treatment, against the standard treatment alone, to see if it works better.